Omeros OMER
Omeros Corp · Nasdaq · Pharmaceutical Preparations
$17.88+2.23%close on Oct. 28, 2026 · volume 604K · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Sept. 23, 2026 | David J. Borges VP, Finance & CAO | Sold 10b5-1 plan | 10,000 | $20.95 | $209,500 |
| Sept. 22, 2026 | David J. Borges VP, Finance & CAO | Sold 10b5-1 plan | 10,000 | $20.95 | $209,500 |
| Aug. 31, 2026 | Peter B. Cancelmo VP, General Counsel | Sold | 25,000 | $18.54 | $463,540 |
| Aug. 28, 2026 | Peter B. Cancelmo VP, General Counsel | Sold | 25,000 | $18.65 | $466,128 |
| Aug. 27, 2026 | Arnold C. Hanish director | Sold | 10,000 | $18.95 $18.88-$19.02 | $189,462 |
| Aug. 26, 2026 | Arnold C. Hanish director | Sold | 5,000 | $18.53 | $92,632 |
| Aug. 24, 2026 | David J. Borges VP, Finance & CAO | Sold 10b5-1 plan | 906 | $19.10 | $17,305 |
| Aug. 21, 2026 | David J. Borges VP, Finance & CAO | Sold 10b5-1 plan | 10,000 | $18.95 | $189,500 |
| Aug. 20, 2026 | Thomas J. Cable director | Sold | 15,000 | $18.45 | $276,772 |
| Aug. 13, 2026 | David J. Borges VP, Finance & CAO | Sold 10b5-1 plan | 5,000 | $16.95 | $84,750 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 14 →Departure/appointment of directors or officers